Comparison · NCT00884117-sae
Participants Treated With Oseltamivir vs Participants Not Treated With Oseltamivir: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Participants Treated With Oseltamivir vs Participants Not Treated With Oseltamivir: serious adverse events. Trial comparisons, record NCT00884117-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00884117-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00931 | 0.00626 | 0.0138 | wilson | |
| Risk in group 2 | 0.00557 | 0.00311 | 0.00995 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00374 | -0.00159 | 0.00887 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.67 | 0.821 | 3.4 | log | |
| Odds ratio, group 1 over group 2 | 1.68 | 0.82 | 3.43 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Participants Treated With Oseltamivir than on Participants Not Treated With Oseltamivir | 267 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Participants Treated With Oseltamivir | Otherwise healthy/non-immunocompromised adults and children with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness were enrolled during Years 1 to 7 of the overall study. Participants receiving antiviral treatment with oseltamivir (according to local practice standards) were followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. | 24 | 2,578 | EG000 |
| Group 2 | Participants Not Treated With Oseltamivir | Otherwise healthy/non-immunocompromised adults and children with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness were enrolled during Years 1 to 7 of the overall study. Participants not receiving oseltamivir, including no treatment or other antiviral treatment, were followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. | 11 | 1,975 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From Baseline (Day 1) to Day 10; assessed on Days 1, 3, 6, 10
Source ClinicalTrials.gov
Trial
- Title
- Influenza Resistance Information Study
- NCT number
- NCT00884117
- Phases
- Conditions
- Influenza
- Interventions
- Oseltamivir
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2016-07-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00884117?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00884117-sae